Ursodeoxycholic acid and Pulmozyme drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ursodeoxycholic acid (ursodiol) and Pulmozyme (dornase alfa). Common drug interactions include distal intestinal obstruction syndrome among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Ursodeoxycholic acid and Pulmozyme. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Ursodeoxycholic acid?

Ursodeoxycholic acid has active ingredients of ursodiol. It is often used in biliary cirrhosis primary. eHealthMe is studying from 7,528 Ursodeoxycholic acid users. Check the latest studies of Ursodeoxycholic acid.

What is Pulmozyme?

Pulmozyme has active ingredients of dornase alfa. It is often used in cystic fibrosis. eHealthMe is studying from 20,012 Pulmozyme users. Check the latest studies of Pulmozyme.

On Jul, 16, 2026

18 people who take Ursodeoxycholic acid and Pulmozyme together, and have interactions are studied.

Ursodeoxycholic acid and Pulmozyme drug interactions.

What are the common drug interactions of Ursodeoxycholic Acid and Pulmozyme, by gender? *:

female:

Distal intestinal obstruction syndrome (blockage of the intestines by thickened stool and occurs in individuals with cystic fibrosis)
Abdominal pain
Anxiety
Blood bilirubin increased
Burkholderia cepacia complex infection (complex infection by group of bacteria burkholderia cepacia -resistant to common antibiotics)
Constipation
Coombs direct test positive
Cough
Forced expiratory volume decreased (decreased lung expired air volume)
Grand mal convulsion (a type of generalized seizure that affects the entire brain)

male:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pneumonia
Suicidal ideation
Respiratory failure (inadequate gas exchange by the respiratory system)
Cystic fibrosis lung (fibrosis with cyst in the lung)
Drug ineffective
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Forced expiratory volume decreased (decreased lung expired air volume)
General physical health deterioration (weak health status)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

What are the common drug interactions of Ursodeoxycholic Acid and Pulmozyme, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Blood bilirubin increased
Immune thrombocytopenic purpura (destruction of blood platelets due to the presence of antiplatelet auto antibodies)
Neutropenia (an abnormally low number of neutrophils)

10-19:

Coombs direct test positive
Cystic fibrosis lung (fibrosis with cyst in the lung)
Drug ineffective
General physical health deterioration (weak health status)
Haemoglobin decreased
Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
Haemolytic anaemia drug induced (anaemia due to haemolysis due to use of medications)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Photopsia (presence of perceived flashes of light)
Portal hypertension (increase in the blood pressure within a system of veins called the portal venous system)

20-29:

Respiratory failure (inadequate gas exchange by the respiratory system)
Syncope (loss of consciousness with an inability to maintain postural tone)
Burkholderia cepacia complex infection (complex infection by group of bacteria burkholderia cepacia -resistant to common antibiotics)
Cough
Forced expiratory volume decreased (decreased lung expired air volume)
Grand mal convulsion (a type of generalized seizure that affects the entire brain)

30-39:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pneumonia
Respiratory failure (inadequate gas exchange by the respiratory system)
Forced expiratory volume decreased (decreased lung expired air volume)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Pulmonary haemorrhage (acute bleeding from the lung)

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis Related Diabetes: 4 people, 22.22%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 3 people, 16.67%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 3 people, 16.67%
Pneumonia: 2 people, 11.11%
Pancreatic Insufficiency: 2 people, 11.11%
Osteoporosis (bones weak and more likely to break): 2 people, 11.11%
Liver Disorder (liver diseases): 2 people, 11.11%
Hypovitaminosis (any of several diseases caused by deficiency of one or more vitamins): 1 person, 5.56%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 1 person, 5.56%
Diabetes: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ursodeoxycholic acid and Pulmozyme?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously